GSK plc vs Clear Secure Inc — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Clear Secure Inc trades at $54.57 (market cap $5.51B). The key difference: GSK plc is far larger — about 18.4× Clear Secure Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | YOU | |
|---|---|---|
Market Cap | $101.34B | $5.51B |
Sector | Health | Technology |
52-Week High | $61.18 | $62.36 |
52-Week Low | $36.20 | $28.84 |
Enterprise Value | $121.95B | $4.82B |
Dividend Yield | 3.49% | 1.1% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Clear Secure (YOU) trades at $54.62, up 2.02% today, with a neutral technical signal and bullish moving averages. The company shows strong profitability with a 65.48% gross margin and 81.15% ROE, though valuations are elevated with a P/E of 43.72. Recent Q1 2026 earnings beat expectations, and expansion initiatives like the AWS integration and Indianapolis airport launch support growth. Cash flow improved to $83M net in 2026 from $18M in 2025.
The outlook is cautiously optimistic, with a consensus price target of $56.67 offering modest upside. Key opportunities include member growth and free cash flow strength, while risks involve high valuation multiples and competitive pressures. Analyst sentiment is balanced with 44% buy ratings, but execution on guidance remains critical for sustained momentum.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →